News and Press releases

Oxcia AB (publ) publishes annual report

May 16, 2023 · Press releases

Read article

Oxcia AB (publ) publishes interim report fort the first quarter 2023

April 26, 2023 · Press releases

Read article

Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients

April 3, 2023 · Press releases

Read article

Three abstracts on OXC-101 selected for poster presentations at AACR 2023

March 30, 2023 · Press releases

Read article

New pre-clinical study shows that OXC-201 may be a promising treatment for IPF (pulmonary fibrosis)

March 2, 2023 · Press releases

Read article

The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.

February 24, 2023 · Press releases

Read article

Oxcia AB publishes Year-End Report for 2022

February 15, 2023 · Press releases

Read article

Data show OXC-201 may be a promising treatment for allergic asthma.

October 21, 2022 · Press releases

Read article

Enrolment completed and recommended phase II dose reached for OXC-101

October 14, 2022 · Press releases

Read article

Oxcia AB is strengthening the organization further

September 6, 2022 · Press releases

Read article

New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)

March 23, 2022 · Press releases

Read article

Oxcia reports positive interim data from clinical phase I study in advanced solid cancers

January 17, 2022 · Press releases

Read article